Skip to main content

Table 1 Number and proportion (%) of nalidixic acid-, ciprofloxacin- and multidrug-resistant Salmonella Typhi isolated between 2002 and 2013

From: Antimicrobial susceptibility of travel-related Salmonella enterica serovar Typhi isolates detected in Switzerland (2002–2013) and molecular characterization of quinolone resistant isolates

  

Resistance pattern

Total no. of isolates

 

NAL

CIP

MDRa

 

Year

no. (%)

no. (%)

no. (%)

10

2002

2 (20)

0 (0)

0 (0)

16

2003

6 (37.5)

0 (0)

2 (12.5)

13

2004

5 (38.5)

1 (7.7)

2 (15.4)

16

2005

5 (31.3)

3 (18.8)

1 (6.3)

16

2006

9 (56.3)

3 (18.8)

0 (0)

18

2007

15 (83.3)

5 (27.8)

3 (16.7)

16

2008

9 (56.3)

3 (18.8)

3 (18.8)

18

2009

14 (77.8)

1 (5.6)

1 (5.6)

24

2010

20 (83.3)

6 (25)

4 (16.7)

15

2011

9 (60)

4 (26.7)

3 (20)

12

2012

7 (58.3)

3 (25)

3 (25)

18

2013

12 (66.7)

10 (55.6)

0 (0)

Total

    

192

 

113 (58.9)

39 (20.3)

22 (11.5)

  1. Abbreviations: NAL, nalidixic acid; CIP, ciprofloxacin; MDR, multidrug resistant
  2. aMultidrug resistance is defined as resistance to ampicillin, trimethoprim/sulfamethoxazole and chloramphenicol (13)